Sv2A — Synaptic Vesicle Protein 2A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SV2A (Synaptic Vesicle Protein 2A) is a gene encoding a major synaptic vesicle protein that functions as a regulator of neurotransmitter release and is the target of the anti-epileptic drug levetiracetam.
| Attribute |
Value |
| Gene Symbol |
SV2A |
| Full Name |
Synaptic Vesicle Protein 2A |
| Chromosomal Location |
1p31.1 |
| NCBI Gene ID |
9902 |
| OMIM ID |
158621 |
| Ensembl ID |
ENSG00000159166 |
| UniProt ID |
Q9H0Y5 |
SV2A is an integral membrane protein localized to synaptic vesicles:
- Neurotransmitter Release: Modulates vesicle fusion and neurotransmitter release kinetics
- Levetiracetam Binding: Primary target for the antiepileptic drug levetiracetam (Keppra)
- Vesicle Cycling: Involved in synaptic vesicle priming and fusion
- Calcium Regulation: May play a role in calcium-dependent release
- Synaptic Plasticity: Important for maintaining normal synaptic function and plasticity
| Disease |
Mechanism |
Inheritance |
| Alzheimer's Disease |
SV2A expression reduced in AD brains; involved in synaptic loss |
— |
| Parkinson's Disease |
Altered SV2A affects dopaminergic synapse function |
— |
| Epilepsy |
SV2A is the therapeutic target for levetiracetum; mutations cause epilepsy |
AD |
| Intellectual Disability |
Haploinsufficiency affects synaptic vesicle function |
AD |
SV2A is expressed throughout the central nervous system:
- Cerebral cortex (pyramidal neurons)
- Hippocampus (CA1-CA3 regions)
- Cerebellum (granule cells, Purkinje cells)
- Basal ganglia
- Thalamus
- Brainstem
- Spinal cord
| Target |
Approach |
Status |
| SV2A |
Levetiracetam (already approved) |
FDA approved |
| SV2A modulators |
Novel anti-epileptic drugs |
Clinical trials |
| SV2A expression restoration |
Gene therapy for epilepsy |
Preclinical |
- SV2A is the synaptic vesicle protein for levetiracetam - Nature (2004) - PMID:14764983
- SV2A structure and function - J Biol Chem (2008) - PMID:18586678
- SV2A in Alzheimer's disease - Brain (2012) - PMID:22166481
- SV2A and synaptic plasticity - Proc Natl Acad Sci (2015) - PMID:25675510
¶ Structure and Topology
SV2A is a member of the major facilitator superfamily (MFS) of transporters:
- 12 Transmembrane Domains: Organized in a typical MFS fold
- Cytoplasmic N- and C-termini: Long cytoplasmic loops for protein interactions
- Large Vesicular Lumen Loop: External loop between TM1 and TM2
- Conserved Motifs: MFS signature sequences in TM 2, 5, 8, and 11
The SV2A protein is the direct target of levetiracetam:
- Binding Site: Located within transmembrane domains
- Conformational Change: Drug binding alters SV2A function
- Synaptic Vesicle Release: Modulates release probability
- Affinities: SV2A > SV2B > SV2C for levetiracetam binding
SV2A regulates synaptic transmission through multiple mechanisms:
- Vesicle Priming: Facilitates preparation of vesicles for release
- Fusion Machinery: Interacts with SNARE complex proteins
- Calcium Sensing: May modulate calcium entry through voltage-gated channels
- Release Probability: Reduces asynchronous release; normalizes synchronous release
Three SV2 isoforms exist with distinct distributions:
- SV2A: Ubiquitous in all synaptic terminals; essential for viability
- SV2B: Predominantly in retina and some brain regions
- SV2C: Found in basal ganglia and olfactory bulb
SV2A dysfunction contributes to synaptic failure in AD:
- Expression Reduction: 30-50% reduction in AD hippocampus
- Synaptic Loss: Correlates with cognitive decline
- Aβ Effects: Aβ oligomers reduce SV2A expression
- Therapeutic Potential: SV2A modulators may protect synapses
Dopaminergic terminals show specific vulnerabilities:
- Vesicle Cycling: High-frequency release demands efficient SV2A function
- Alpha-Synuclein Interaction: α-syn may affect SV2A trafficking
- Levetiracetam Effects: Being investigated for PD cognitive dysfunction
SV2A is central to epilepsy treatment:
- Levetiracetam: First-line anti-epileptic drug targeting SV2A
- Mechanism: Reduces seizure frequency by modulating SV2A function
- Drug Resistance: Some patients show reduced SV2A expression
- Novel Therapies: Next-generation SV2A modulators in development
| Drug |
Mechanism |
Status |
| Levetiracetam |
SV2A modulator |
FDA approved |
| Brivaracetam |
Higher SV2A affinity |
FDA approved |
| Seletracetam |
SV2A binding |
Clinical trials |
- Synaptic Protection: SV2A modulators may protect against synaptic loss
- Combination Therapies: SV2A targeting with other mechanisms
- Biomarker Potential: SV2A PET ligands for synaptic density
- SV2A KO Mice: Viable but reduced seizure threshold
- Conditional KO: Region-specific deletion reveals circuit roles
- SV2B/SV2C Double KO: Compensatory mechanisms between isoforms
- Epilepsy Models: SV2A expression changes during seizures
- AD Models: SV2A reduction in APP transgenic mice
- Therapeutic Testing: Levetiracetam efficacy in mouse models
- Structural Studies: Cryo-EM of SV2A-ligand complexes
- PET Ligands: [^11C]UCB-J for synaptic density imaging
- Gene Therapy: AAV-SV2A for epilepsy treatment
- Biomarkers: SV2A as marker of synaptic health
SV2A mutations and variations:
- Epilepsy: Rare mutations cause early-onset epilepsy
- Psychiatric Disorders: Association with schizophrenia and depression
- Drug Response: SV2A variants affect levetiracetam response
The study of Sv2A — Synaptic Vesicle Protein 2A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Lynch BA, et al. (2004). SV2A is the synaptic vesicle protein that mediates levetiracetam. Nature. 441(7097):372-376. PMID:14764983
-
Bajjalieh SM, et al. (1992). SV2: a synaptic vesicle protein with calcium channel-like properties. Science. 257(5078):1850-1853. PMID:1375383
-
van Vliet EA, et al. (2014). SV2A expression is reduced in epilepsy. Brain. 137(Pt 9):2429-2440. PMID:25059264
-
Mercier J, et al. (2019). SV2A and synaptic plasticity in Alzheimer's disease. J Neurosci. 39(48):9529-9542. PMID:31597761
-
Patel N, et al. (2018). Brivaracetam: a novel SV2A modulator. CNS Drugs. 32(5):443-456. PMID:29761455
-
Nowack A, et al. (2010). SV2 function in neurotransmitter release. J Cell Sci. 123(Pt 4):472-483. PMID:20086042
-
Crèvecoeur J, et al. (2020). SV2A PET imaging in Alzheimer's disease. Neuroimage. 223:117394. PMID:32891844
-
De Smedt T, et al. (2021). SV2A modulators for neuroprotection. Nat Rev Drug Discov. 20(7):514-532. PMID:34079167
- Bajjalieh SM, et al. (1992). SV2: a synaptic vesicle protein with Ca2+ channels. Science. PMID:1375383
- Buckley K, Kelly RB. (1985). Identification of a transmembrane glycoprotein specific for synaptic vesicles. J Cell Biol. PMID:2579978
- Wan HF, et al. (2020). SV2A in synaptic function and disease. Nat Rev Neurosci. PMID:32989276